Insiders Give Up US66k As BioAtla Stock Drops To US1.31
| BCAB Stock | USD 1.18 0.13 9.92% |
About 63% of all Bioatla's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Bioatla suggests that some traders are interested. The current market sentiment, together with Bioatla's historical and current headlines, can help investors time the market. In addition, many technical investors use Bioatla stock news signals to limit their universe of possible portfolio assets.
Bioatla |
The recent price decline of 19 percent in BioAtla, Inc.s stock may have disappointed insiders who bought...
Read at finance.yahoo.com
 |
Bioatla Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Bioatla can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bioatla Fundamental Analysis
We analyze Bioatla's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioatla using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioatla based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Bioatla is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Bioatla Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bioatla stock to make a market-neutral strategy. Peer analysis of Bioatla could also be used in its relative valuation, which is a method of valuing Bioatla by comparing valuation metrics with similar companies.
Peers
Bioatla Related Equities
| ACRV | Acrivon Therapeutics, | 3.00 | ||||
| AVTE | Aerovate Therapeutics | 1.19 | ||||
| ERAS | Erasca | 0.38 | ||||
| GLUE | Monte Rosa | 0.13 | ||||
| DSGN | Design Therapeutics | 0.64 | ||||
| ANTX | AN2 Therapeutics | 0.74 | ||||
| PMVP | Pmv Pharmaceuticals | 2.56 | ||||
| ADAG | Adagene | 2.86 | ||||
| IKNA | Ikena Oncology | 4.32 | ||||
| NRIX | Nurix Therapeutics | 4.44 | ||||
| OLMA | Olema Pharmaceuticals | 4.72 | ||||
| STTK | Shattuck Labs | 6.09 | ||||
| KYMR | Kymera Therapeutics | 7.66 | ||||
| RZLT | Rezolute | 8.11 | ||||
| NAUT | Nautilus Biotechnology | 8.59 | ||||
| PASG | Passage Bio | 8.96 | ||||
| CCCC | C4 Therapeutics | 9.63 | ||||
| IPSC | Century Therapeutics | 10.26 | ||||
| FHTX | Foghorn Therapeutics | 10.89 |
Complementary Tools for Bioatla Stock analysis
When running Bioatla's price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |